First Bellwether Trial in Roundup MDL Reaches End of Initial Science-Heavy Phase
A San Francisco federal jury is considering whether Monsanto's Roundup weedkiller was a significant factor contributing to Edwin Hardeman's cancer diagnosis.
March 12, 2019 at 04:30 PM
5 minute read
A lawyer representing a Northern California man who claims that exposure to Monsanto Co.'s Roundup weedkiller caused him to develop cancer urged a San Francisco jury to consider the amount and duration of his exposure.
Aimee Wagstaff of Andrus Wagstaff on Tuesday pointed to expert testimony that concluded that her client Edwin Hardeman sprayed about 6,000 gallons of Roundup on his property over a 26-year span. Monsanto's experts, she argued, didn't consider the amount her client sprayed or the duration of his exposure when they concluded that Roundup wasn't a significant factor contributing to his cancer.
“The dose makes the poison,” Wagstaff repeated during closing arguments Tuesday in the first bellwether trial in the multidistrict Roundup litigation pending before U.S. District Judge Vince Chhabria of the Northern District of California.
Chhabria bifurcated the trial to frontload the question of whether or not Monsanto's Roundup herbicide was a significant cause of plaintiff Hardeman's non-Hodgkins lymphoma. If the jury unanimously finds that a preponderance of the evidence shows that Roundup was a significant factor contributing to Hardeman's cancer, the case will move onto a second phase to consider what Monsanto knew, how the company conducted itself, and potential damages. A finding that Roundup was not a significant factor would be a victory for the defense and the end of the first bellwether trial, but not the MDL. If the six-member jury is unable to reach a unanimous verdict, the result would be a mistrial, and Hardeman's case could be tried again.
Closing arguments Tuesday went significantly smoother for Wagstaff than the opening of trial did. Chhabria interrupted Wagstaff's opening repeatedly and later sanctioned her $500 for what he called “obvious violations” of his pretrial orders during her opening presentation. The judge also ordered Wagstaff to hand over a list of every other attorney who worked on the opening within two weeks of the end of Hardeman's trial for additional possible sanctions.
The stakes are significant for Monsanto's parent company Bayer AG, which last year was hit with a $289 million verdict in San Francisco Superior Court in a Roundup case outside the MDL proceedings. The state court judge overseeing that case, however, slashed the award by more than $200 million.
Pretrial and away from the jury, Chhabria has expressed skepticism about the strength of plaintiffs' scientific evidence. In July, he narrowly allowed plaintiffs' cases in the MDL to move forward, but called evidence that glyphosate—the active ingredient in Roundup—causes non-Hodgkin's lymphoma “shaky” but “admissible.” He wrote that plaintiffs had a “daunting challenge” to prove causation.
Aside from the trial structure, Hardeman's case has some significant differences from the state court trial that yielded the blockbuster verdict. The plaintiff in the state case, Dewayne “Lee” Johnson, was diagnosed with non-Hodgkin's lymphoma, or NHL, after spraying a Monsanto herbicide as part of his job as a school groundskeeper. Johnson's case was fast-tracked for trial because of his dire prognosis. Hardeman, by contrast, is in remission from cancer and developed NHL after using Roundup on his own property to clear poison oak and weeds from hiking trails and his driveway. He also had Hepatitis for decades, something that Monsanto's lawyers argued was a significant risk factor for him contracting NHL.
But in her closings, Wagstaff pointed out that Hardeman's Hepatitis never resurfaced throughout his six rounds of chemotherapy to treat his cancer. “Not one time did the Hep C ever show up,” she said. “So where are the facts of this Hep C swimming around at undetectable level? They're just not there.”
Brian Stekloff, a lawyer at Wilkinson Walsh + Eskovitz who is representing Monsanto in the Hardeman trial, pointed out that the plaintiff's treating physicians had never asked about his Roundup use or tied it to his diagnosis.
“Roundup did not factor into their treatment, whatsoever,” he said. He also said that the Hardeman's lawyers were falsely trying to make the case an issue of “Roundup versus Hepatitis C.” In reality, he argued, that Hardeman's causation expert had testified that Roundup was the primary factor driving his cancer.
“The case they have presented to you is that it is Roundup and Roundup only,” he said “No one has come into this courtroom and said it could have been both.”
Stekloff further argued that the largest human study to look at whether use of the active ingredient in Roundup caused cancer—a long-term study of agricultural workers called the Agricultural Health Study—found that levels of NHL among those exposed were similar to those in the general population—about 1 percent in both. Stekloff said that “if what they're saying is true if Roundup is this huge problem that is causing cancer everywhere” you would expect to see a spike in NHL cases in the wake of the exponential increase of Roundup use since the 1990s.
The number of cases, he said, has remained steady.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
NOT FOR REPRINT
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
You Might Like
View All'Close Our Borders?' Senate Judiciary Committee Examines Economics, Legal Predicate for Mass Deportation Proposal
3 minute readA Judge Asks: Is It Time to End Ken Feinberg's Roundup Settlement Program?
7 minute readTrending Stories
- 1Fisher & Phillips Elects 25 New Partners In 15 Cities
- 2New York State Bar Outlines 2025 Legislative Priorities, Aiming for Fairness, Equity
- 3Family of 'Cop City' Activist Killed by Ga. Troopers Files Federal Lawsuit
- 4Houston Appeals Court Split Over Race Discrimination Suit Involving COVID-19 Vaccine Distribution
- 5‘It's Your Funeral’: On Avoiding Damaging Your Client’s Case With Uncivil Behavior
Who Got The Work
Michael G. Bongiorno, Andrew Scott Dulberg and Elizabeth E. Driscoll from Wilmer Cutler Pickering Hale and Dorr have stepped in to represent Symbotic Inc., an A.I.-enabled technology platform that focuses on increasing supply chain efficiency, and other defendants in a pending shareholder derivative lawsuit. The case, filed Oct. 2 in Massachusetts District Court by the Brown Law Firm on behalf of Stephen Austen, accuses certain officers and directors of misleading investors in regard to Symbotic's potential for margin growth by failing to disclose that the company was not equipped to timely deploy its systems or manage expenses through project delays. The case, assigned to U.S. District Judge Nathaniel M. Gorton, is 1:24-cv-12522, Austen v. Cohen et al.
Who Got The Work
Edmund Polubinski and Marie Killmond of Davis Polk & Wardwell have entered appearances for data platform software development company MongoDB and other defendants in a pending shareholder derivative lawsuit. The action, filed Oct. 7 in New York Southern District Court by the Brown Law Firm, accuses the company's directors and/or officers of falsely expressing confidence in the company’s restructuring of its sales incentive plan and downplaying the severity of decreases in its upfront commitments. The case is 1:24-cv-07594, Roy v. Ittycheria et al.
Who Got The Work
Amy O. Bruchs and Kurt F. Ellison of Michael Best & Friedrich have entered appearances for Epic Systems Corp. in a pending employment discrimination lawsuit. The suit was filed Sept. 7 in Wisconsin Western District Court by Levine Eisberner LLC and Siri & Glimstad on behalf of a project manager who claims that he was wrongfully terminated after applying for a religious exemption to the defendant's COVID-19 vaccine mandate. The case, assigned to U.S. Magistrate Judge Anita Marie Boor, is 3:24-cv-00630, Secker, Nathan v. Epic Systems Corporation.
Who Got The Work
David X. Sullivan, Thomas J. Finn and Gregory A. Hall from McCarter & English have entered appearances for Sunrun Installation Services in a pending civil rights lawsuit. The complaint was filed Sept. 4 in Connecticut District Court by attorney Robert M. Berke on behalf of former employee George Edward Steins, who was arrested and charged with employing an unregistered home improvement salesperson. The complaint alleges that had Sunrun informed the Connecticut Department of Consumer Protection that the plaintiff's employment had ended in 2017 and that he no longer held Sunrun's home improvement contractor license, he would not have been hit with charges, which were dismissed in May 2024. The case, assigned to U.S. District Judge Jeffrey A. Meyer, is 3:24-cv-01423, Steins v. Sunrun, Inc. et al.
Who Got The Work
Greenberg Traurig shareholder Joshua L. Raskin has entered an appearance for boohoo.com UK Ltd. in a pending patent infringement lawsuit. The suit, filed Sept. 3 in Texas Eastern District Court by Rozier Hardt McDonough on behalf of Alto Dynamics, asserts five patents related to an online shopping platform. The case, assigned to U.S. District Judge Rodney Gilstrap, is 2:24-cv-00719, Alto Dynamics, LLC v. boohoo.com UK Limited.
Featured Firms
Law Offices of Gary Martin Hays & Associates, P.C.
(470) 294-1674
Law Offices of Mark E. Salomone
(857) 444-6468
Smith & Hassler
(713) 739-1250